CD30 in systemic mastocytosis.

Abstract

CD30 is a transmembrane receptor, normally not expressed by mast cells, which regulates proliferation/apoptosis and antibody responses. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. This article highlights the expression profile and role of CD30 and CD30L in physiologic and pathologic conditions, the applicability of CD30 as a marker for systemic mastocytosis, the consequences of mast cell-expressed CD30, and the possibility of future anti-CD30 based cytoreductive therapies.

• Authors: Bjorn van Anrooij, Philip M Kluin, Joanne N G Oude Elberink, Johanna C Kluin-Nelemans
• Journal: Immunology and allergy clinics of North America (Immunol Allergy Clin North Am) Vol. 34 Issue 2 Pg. 341-55 (May 2014) ISSN: 1557-8607 [Electronic] United States
• PMID: 24745678 (Publication Type: Journal Article, Review)
• Copyright: Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antibodies
• CD30 Ligand
• Ki-1 Antigen
• TNFSF8 protein, human

Topics

• Adult
• Antibodies (therapeutic use)
• B-Lymphocytes (immunology, pathology)
• CD30 Ligand (blood, genetics, immunology)
• Gene Expression Regulation, Neoplastic
• Humans
• Ki-1 Antigen (antagonists & inhibitors, blood, genetics, immunology)
• Lymphocyte Activation
• Mast Cells (immunology, pathology)
• Mastocytosis, Systemic (diagnosis, drug therapy, genetics, pathology)
• Prognosis
• Signal Transduction
• T-Lymphocytes (immunology, pathology)